Larimar Therapeutics, (id:6724 LRMR)
6.16 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:56:18 PM)
Exchange closed, opens in 1 day 10 hours
0.00 USD (0.00%)
-4.20 USD (-4.20%)
-22.52 USD (-22.52%)
-13.12 USD (-13.12%)
74.50 USD (74.50%)
666.17 USD (666.17%)
-70.67 USD (-70.67%)
-69.20 USD (-69.20%)
About Larimar Therapeutics,
Market Capitalization 391.13M
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
| Headquarters (address) |
Three Bala Plaza East Bala Cynwyd 19004 PA United States |
| Phone | 844 511 9056 |
| Website | https://www.larimartx.com |
| Employees | 42 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LRMR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.19 - 13.68 |
| Market Capitalization | 391.13M |
| P/E trailing | -7.35 |
| P/E forward | -3.98 |
| Price/Book | 1.97 |
| Beta | 0.713 |
| EPS | -1.15 |
| EPS United States (ID:6, base:3403) | 24.22 |